Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 284

1.

Vaccine against peanut allergy based on engineered Virus-Like-Particles displaying single major peanut allergens.

Storni F, Zeltins A, Balke I, Heath MD, Kramer MF, Skinner MA, Zha L, Roesti E, Engeroff P, Muri L, von Werdt D, Gruber T, Cragg M, Mlynarczyk M, Kündig TM, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2019 Dec 19. pii: S0091-6749(19)31709-9. doi: 10.1016/j.jaci.2019.12.007. [Epub ahead of print]

2.

Interleukin 31 in insect bite hypersensitivity - Alleviating clinical symptoms by active vaccination against itch.

Olomski F, Fettelschoss V, Jonsdottir S, Birkmann K, Thoms F, Marti E, Bachmann MF, Kündig TM, Fettelschoss-Gabriel A.

Allergy. 2019 Dec 9. doi: 10.1111/all.14145. [Epub ahead of print]

PMID:
31816097
3.

Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.

Gilfillan CB, Wang C, Mohsen MO, Rufer N, Hebeisen M, Allard M, Verdeil G, Irvine DJ, Bachmann MF, Speiser DE.

Eur J Immunol. 2019 Nov 30. doi: 10.1002/eji.201948355. [Epub ahead of print]

4.

Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies.

Tytgat HLP, Lin CW, Levasseur MD, Tomek MB, Rutschmann C, Mock J, Liebscher N, Terasaka N, Azuma Y, Wetter M, Bachmann MF, Hilvert D, Aebi M, Keys TG.

Nat Commun. 2019 Nov 27;10(1):5403. doi: 10.1038/s41467-019-13283-2.

5.

Virus-like particles for vaccination against cancer.

Mohsen MO, Speiser DE, Knuth A, Bachmann MF.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jan;12(1):e1579. doi: 10.1002/wnan.1579. Epub 2019 Aug 27. Review.

6.

Virus-Specific Secondary Plasma Cells Produce Elevated Levels of High-Avidity Antibodies but Are Functionally Short Lived.

Krueger CC, Thoms F, Keller E, Vogel M, Bachmann MF.

Front Immunol. 2019 Aug 6;10:1831. doi: 10.3389/fimmu.2019.01831. eCollection 2019.

7.

CD23 provides a noninflammatory pathway for IgE-allergen complexes.

Engeroff P, Caviezel F, Mueller D, Thoms F, Bachmann MF, Vogel M.

J Allergy Clin Immunol. 2020 Jan;145(1):301-311.e4. doi: 10.1016/j.jaci.2019.07.045. Epub 2019 Aug 19.

8.

Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands-A Role for CCL2.

Gomes AC, Mohsen MO, Mueller JE, Leoratti FMS, Cabral-Miranda G, Bachmann MF.

Front Immunol. 2019 Aug 2;10:1679. doi: 10.3389/fimmu.2019.01679. eCollection 2019.

9.

Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection.

Cabral-Miranda G, Lim SM, Mohsen MO, Pobelov IV, Roesti ES, Heath MD, Skinner MA, Kramer MF, Martina BEE, Bachmann MF.

Vaccines (Basel). 2019 Jul 23;7(3). pii: E72. doi: 10.3390/vaccines7030072.

10.

Type of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine Design.

C Gomes A, Roesti ES, El-Turabi A, Bachmann MF.

Vaccines (Basel). 2019 Jun 4;7(2). pii: E47. doi: 10.3390/vaccines7020047.

11.

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.

Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE, Bachmann MF.

Front Immunol. 2019 May 15;10:1015. doi: 10.3389/fimmu.2019.01015. eCollection 2019.

12.

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 May 23;7(1):137. doi: 10.1186/s40425-019-0616-y.

13.

Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.

Thoms F, Jennings GT, Maudrich M, Vogel M, Haas S, Zeltins A, Hofmann-Lehmann R, Riond B, Grossmann J, Hunziker P, Fettelschoss-Gabriel A, Senti G, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2019 Jul;144(1):193-203. doi: 10.1016/j.jaci.2019.01.050. Epub 2019 May 2.

14.

Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 Apr 26;7(1):114. doi: 10.1186/s40425-019-0587-z. Erratum in: J Immunother Cancer. 2019 May 23;7(1):137.

15.

RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion.

Krueger CC, Thoms F, Keller E, Leoratti FMS, Vogel M, Bachmann MF.

Front Immunol. 2019 Apr 5;10:736. doi: 10.3389/fimmu.2019.00736. eCollection 2019.

16.

Immunogenicity and Immunodominance in Antibody Responses.

Vogel M, Bachmann MF.

Curr Top Microbiol Immunol. 2019 Mar 28. doi: 10.1007/82_2019_160. [Epub ahead of print]

PMID:
30919087
17.

Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.

von Loga IS, El-Turabi A, Jostins L, Miotla-Zarebska J, Mackay-Alderson J, Zeltins A, Parisi I, Bachmann MF, Vincent TL.

Ann Rheum Dis. 2019 May;78(5):672-675. doi: 10.1136/annrheumdis-2018-214489. Epub 2019 Mar 12.

18.

The thioredoxin-1 and glutathione/glutaredoxin-1 systems redundantly fuel murine B-cell development and responses.

Muri J, Thut H, Heer S, Krueger CC, Bornkamm GW, Bachmann MF, Kopf M.

Eur J Immunol. 2019 May;49(5):709-723. doi: 10.1002/eji.201848044. Epub 2019 Mar 1.

PMID:
30802940
19.

A vaccine against Alzheimer`s disease: anything left but faith?

Bachmann MF, Jennings GT, Vogel M.

Expert Opin Biol Ther. 2019 Jan;19(1):73-78. doi: 10.1080/14712598.2019.1554646. Epub 2018 Dec 17. Review.

PMID:
30526133
20.

The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.

Engeroff P, Bachmann MF.

Expert Rev Vaccines. 2019 Jan;18(1):1-3. doi: 10.1080/14760584.2019.1557522. Epub 2018 Dec 13.

PMID:
30526126

Supplemental Content

Loading ...
Support Center